SI2114933T1 - Piperidinski gpcr-agonisti - Google Patents

Piperidinski gpcr-agonisti

Info

Publication number
SI2114933T1
SI2114933T1 SI200830454T SI200830454T SI2114933T1 SI 2114933 T1 SI2114933 T1 SI 2114933T1 SI 200830454 T SI200830454 T SI 200830454T SI 200830454 T SI200830454 T SI 200830454T SI 2114933 T1 SI2114933 T1 SI 2114933T1
Authority
SI
Slovenia
Prior art keywords
gpcr agonists
piperidine
piperidine gpcr
agonists
obesity
Prior art date
Application number
SI200830454T
Other languages
English (en)
Slovenian (sl)
Inventor
Matthew Colin Thor Fyfe
John Keily
Simon Andrew Swain
Original Assignee
Prosidion Ltd Windrush Court
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0700123A external-priority patent/GB0700123D0/en
Priority claimed from GB0719760A external-priority patent/GB0719760D0/en
Application filed by Prosidion Ltd Windrush Court filed Critical Prosidion Ltd Windrush Court
Publication of SI2114933T1 publication Critical patent/SI2114933T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
SI200830454T 2007-01-04 2008-01-04 Piperidinski gpcr-agonisti SI2114933T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0700123A GB0700123D0 (en) 2007-01-04 2007-01-04 GPCR agonists
GB0719760A GB0719760D0 (en) 2007-10-10 2007-10-10 GPCR agonists
PCT/GB2008/050010 WO2008081204A1 (en) 2007-01-04 2008-01-04 Piperidine gpcr agonists
EP08702095A EP2114933B1 (en) 2007-01-04 2008-01-04 Piperidine gpcr agonists

Publications (1)

Publication Number Publication Date
SI2114933T1 true SI2114933T1 (sl) 2012-01-31

Family

ID=39203133

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200830454T SI2114933T1 (sl) 2007-01-04 2008-01-04 Piperidinski gpcr-agonisti

Country Status (16)

Country Link
US (1) US20100048632A1 (enExample)
EP (2) EP2114933B1 (enExample)
JP (1) JP2010514828A (enExample)
AT (1) ATE523507T1 (enExample)
BR (1) BRPI0806498A2 (enExample)
CA (1) CA2674348A1 (enExample)
CY (1) CY1112483T1 (enExample)
DK (1) DK2114933T3 (enExample)
EA (1) EA015129B1 (enExample)
ES (1) ES2373181T3 (enExample)
HR (1) HRP20110852T1 (enExample)
PL (1) PL2114933T3 (enExample)
PT (1) PT2114933E (enExample)
RS (1) RS52065B (enExample)
SI (1) SI2114933T1 (enExample)
WO (1) WO2008081204A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2008000017A1 (es) * 2007-01-04 2008-08-01 Prosidion Ltd Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci
WO2009034388A1 (en) 2007-09-10 2009-03-19 Prosidion Limited Compounds for the treatment of metabolic disorders
GB0812648D0 (en) * 2008-07-10 2008-08-20 Prosidion Ltd Compounds
GB0812649D0 (en) * 2008-07-10 2008-08-20 Prosidion Ltd Compounds
GB0904287D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904285D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904284D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
US8293729B2 (en) 2009-06-24 2012-10-23 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical composition and methods relating thereto
JP2012530758A (ja) 2009-06-24 2012-12-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規化合物、医薬組成物及びそれに関する方法
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2547339A1 (en) 2010-03-18 2013-01-23 Boehringer Ingelheim International GmbH Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
GB201006167D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB201006166D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
ITMI20100770A1 (it) 2010-05-03 2011-11-04 Dipharma Francis Srl Procedimento per la preparazione di 3-(4-piridinil)-propanolo e suoi intermedi
TW201209054A (en) 2010-05-28 2012-03-01 Prosidion Ltd Novel compounds
ITMI20100984A1 (it) 2010-05-31 2011-12-01 Dipharma Francis Srl Procedimento per la preparazione di ossadiazoli
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
CN103189053A (zh) 2010-09-01 2013-07-03 艾尼纳制药公司 用于体重控制的5-ht2c激动剂的调节释放剂型
JP2013539470A (ja) 2010-09-01 2013-10-24 アリーナ ファーマシューティカルズ， インコーポレイテッド ロルカセリンと光学活性な酸との塩
SG10201506865WA (en) 2010-09-01 2015-10-29 Arena Pharm Inc Non-hygroscopic salts of 5-ht2c agonists
MX2013002430A (es) 2010-09-01 2013-07-22 Arena Pharm Inc Formas de dosis de disolucion de rápida de agonistas de 5-ht2c.
AR083904A1 (es) 2010-11-18 2013-04-10 Prosidion Ltd Derivados de 1,4-pirrolidinas disustituidos y 3-il-aminas y sus usos en el tratamiento de desordenes metabolicos
GB201114389D0 (en) 2011-08-22 2011-10-05 Prosidion Ltd Novel compounds
CN103958495B (zh) 2011-06-09 2018-06-22 理森制药股份公司 作为gpr-119的调节剂的化合物
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
NZ630488A (en) 2012-06-12 2016-07-29 Chong Kun Dang Pharm Corp Piperidine derivatives for gpr119 agonist
CN110028494A (zh) 2013-11-26 2019-07-19 株式会社钟根堂 酰胺衍生物、其立体异构体或其药学上可接受的盐及包含其的药物组合物
KR101726819B1 (ko) * 2014-10-27 2017-04-13 동아에스티 주식회사 Gpr119 작용 활성을 갖는 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3576810A (en) * 1968-06-20 1971-04-27 Robins Co Inc A H 1-substituted-3-(-4)-aroylpiperidines
FR2713225B1 (fr) 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
DE4222565A1 (de) * 1992-07-09 1994-01-13 Hoechst Ag Meta-substituierte Sechsringaromaten zur Verwendung in Flüssigkristallmischungen
US6100042A (en) 1993-03-31 2000-08-08 Cadus Pharmaceutical Corporation Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
DE4311968A1 (de) * 1993-04-10 1994-10-20 Hoechst Ag Smektische Flüssigkristallmischung
DE4311967A1 (de) * 1993-04-10 1994-10-13 Hoechst Ag Smektische Flüssigkristallmischung
AU7193394A (en) 1993-08-13 1995-03-14 Zeneca Limited Thia- and oxadiazole derivatives and their use as fungicides or insecticides
EP0858457A1 (de) * 1995-10-20 1998-08-19 Dr. Karl Thomae GmbH 5-gliedrige heterocyclen, diese verbindungen enthaltende arzneimittel und deren verwendung sowie verfahren zu ihrer herstellung
CA2262569A1 (en) 1996-08-09 1998-02-19 Norihito Ohi Benzopiperidine derivatives
GB9719496D0 (en) 1997-09-13 1997-11-19 Glaxo Group Ltd G protien chimeras
EP1123391A2 (en) 1998-09-01 2001-08-16 BASF Aktiengesellschaft Methods for improving the function of heterologous g protein-coupled receptors
US6221660B1 (en) 1999-02-22 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding SNORF25 receptor
GB0109103D0 (en) 2001-04-11 2001-05-30 Pfizer Ltd Novel compounds
FR2829027A1 (fr) 2001-08-29 2003-03-07 Aventis Pharma Sa Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson
FR2829028B1 (fr) 2001-08-29 2004-12-17 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de
CA2457922A1 (en) 2001-08-31 2003-03-13 University Of Connecticut Novel pyrazole analogs acting on cannabinoid receptors
JP4313672B2 (ja) 2001-09-21 2009-08-12 ソルベイ・フアーマシユーチカルズ・ベー・ブイ 強力なｃｂ１−拮抗活性を有する４，５−ジヒドロ−１ｈ−ピラゾール誘導体
TWI231757B (en) 2001-09-21 2005-05-01 Solvay Pharm Bv 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity
AU2002333852B2 (en) 2001-09-21 2006-07-13 Solvay Pharmaceuticals B.V. Novel 4,5-dihydro-1H-pyrazole derivativeshaving CB1-antagonistic activity
FR2831883B1 (fr) 2001-11-08 2004-07-23 Sanofi Synthelabo Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
SE0104332D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
SE0104330D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
FR2833842B1 (fr) 2001-12-21 2004-02-13 Aventis Pharma Sa Compositions pharmaceutiques a base de derives d'azetidine
WO2003063781A2 (en) 2002-01-29 2003-08-07 Merck & Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
WO2003075660A1 (en) 2002-03-06 2003-09-18 Merck & Co., Inc. Method of treatment or prevention of obesity
DE60334787D1 (de) 2002-03-12 2010-12-16 Merck Sharp & Dohme Substituierte amide
AR038966A1 (es) 2002-03-18 2005-02-02 Solvay Pharm Bv Derivados de tiazol que tienen actividad antagonista, agonista o agonista parcial de cb1
WO2003082190A2 (en) 2002-03-26 2003-10-09 Merck & Co., Inc. Spirocyclic amides as cannabinoid receptor modulators
ES2192494B1 (es) 2002-03-27 2005-02-16 Consejo Superior De Investigaciones Cientificas Derivados de 1,2,4-triazol con propiedades cannabinoides.
JP2005531520A (ja) 2002-03-28 2005-10-20 メルク　エンド　カムパニー　インコーポレーテッド 置換２，３−ジフェニルピリジン類
CA2480856A1 (en) 2002-04-05 2003-10-23 Merck & Co., Inc. Substituted aryl amides
FR2838438A1 (fr) 2002-04-11 2003-10-17 Sanofi Synthelabo Derives de diphenylpyridine,leur preparation, les compositions pharmaceutiques en contenant
FR2838439B1 (fr) 2002-04-11 2005-05-20 Sanofi Synthelabo Derives de terphenyle, leur preparation, les compositions pharmaceutqiues en contenant
AU2003223510B2 (en) 2002-04-12 2008-05-08 Merck Sharp & Dohme Corp. Bicyclic amides
US6825209B2 (en) 2002-04-15 2004-11-30 Research Triangle Institute Compounds having unique CB1 receptor binding selectivity and methods for their production and use
AU2003250117B2 (en) 2002-07-29 2007-05-10 F. Hoffmann-La Roche Ag Novel benzodioxoles
EP1558252B1 (en) 2002-08-02 2007-10-10 Merck & Co., Inc. Substituted furo [2,3-b]pyridine derivatives
WO2004034968A2 (en) 2002-08-20 2004-04-29 The Regents Of The University Of California Combination therapy for controlling appetites
HRP20050053A2 (en) 2002-09-19 2005-04-30 Solvay Pharmaceuticals B.V. 1 h-1,2,4-triazole-3-carboxamide derivatives as cannabinoid-cb1 receptor ligands
CA2499497A1 (en) 2002-09-27 2004-04-08 Merck & Co., Inc. Substituted pyrimidines
CA2502511A1 (en) 2002-10-18 2004-05-29 Pfizer Products Inc. Cannabinoid receptor ligands and uses thereof
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
EP1575901B1 (en) 2002-12-19 2012-10-10 Merck Sharp & Dohme Corp. Substituted amides
GB0230087D0 (en) 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
TW200412344A (en) 2003-01-02 2004-07-16 Hoffmann La Roche Novel CB 1 receptor inverse agonists
MXPA05007114A (es) 2003-01-02 2005-08-26 Hoffmann La Roche Nuevos agonistas inversos del receptor cb1.
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
EP1599480B1 (de) 2003-02-13 2010-06-30 Sanofi-Aventis Deutschland GmbH Substituierte hexahydro-pyrazino(1,2-a)pyrimidin-4,7-dionderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
PL377660A1 (pl) 2003-02-13 2006-02-06 Sanofi-Aventis Deutschland Gmbh Podstawione przy azocie pochodne heksahydropirazyno [1,2-a] pirymidyno-4,7-dionu, sposób ich wytwarzania i ich zastosowanie jako środków leczniczych
US7169797B2 (en) * 2003-02-14 2007-01-30 Abbott Laboratories Protein-tyrosine phosphatase inhibitors and uses thereof
US20040167188A1 (en) * 2003-02-14 2004-08-26 Zhili Xin Protein-tyrosine phosphatase inhibitors and uses thereof
US20060172019A1 (en) 2003-03-07 2006-08-03 Ralston Stuart H Cannabinoid receptor inverse agonists and neutral antagonists as therapeutic agents for the treatment of bone disorders
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
AR045496A1 (es) * 2003-08-29 2005-11-02 Schering Corp Analolgos de benzimidazolpiperidinas 2- substiyuidas como antagonistas de los receptores de la hormona que concentra melanina selectivos para el tratamiento de la obesidad y trastornos relacionados
US8207147B2 (en) 2003-12-24 2012-06-26 Prosidion Limited Heterocyclic derivatives as GPCR receptor agonists
MX2007005289A (es) 2004-11-02 2007-07-19 Banyu Pharma Co Ltd Derivados de bencimidazol ariloxi-sustituido.
CA2591922A1 (en) 2004-12-24 2006-06-29 Prosidion Limited G-protein coupled receptor (gpr116) agonists and use thereof for treating obesity and diabetes
WO2006067532A1 (en) 2004-12-24 2006-06-29 Prosidion Ltd G-protein coupled receptor agonists
GB0428514D0 (en) 2004-12-31 2005-02-09 Prosidion Ltd Compounds
DOP2006000008A (es) * 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
AU2006264649A1 (en) 2005-06-30 2007-01-11 Prosidion Limited GPCR agonists
JP5114395B2 (ja) 2005-06-30 2013-01-09 プロシディオン・リミテッド Ｇｐｃｒアゴニスト
JP2008545008A (ja) 2005-06-30 2008-12-11 プロシディオン・リミテッド Ｇｐｃｒアゴニスト
WO2007003964A1 (en) 2005-06-30 2007-01-11 Prosidion Limited G-protein coupled receptor agonists
NZ571869A (en) * 2006-04-06 2011-11-25 Prosidion Ltd Heterocyclic GPCR agonists

Also Published As

Publication number Publication date
EP2377863A1 (en) 2011-10-19
EA015129B1 (ru) 2011-06-30
PL2114933T3 (pl) 2012-02-29
HK1135703A1 (en) 2010-06-11
EP2114933B1 (en) 2011-09-07
PT2114933E (pt) 2011-12-20
DK2114933T3 (da) 2012-01-02
WO2008081204A1 (en) 2008-07-10
ATE523507T1 (de) 2011-09-15
US20100048632A1 (en) 2010-02-25
JP2010514828A (ja) 2010-05-06
EP2114933A1 (en) 2009-11-11
RS52065B (sr) 2012-06-30
EA200900877A1 (ru) 2010-02-26
ES2373181T3 (es) 2012-02-01
HRP20110852T1 (hr) 2011-12-31
CA2674348A1 (en) 2008-07-10
BRPI0806498A2 (pt) 2014-04-22
CY1112483T1 (el) 2015-12-09

Similar Documents

Publication Publication Date Title
PL2114933T3 (pl) Piperydyny jako agoniści GPCR
MX2009007180A (es) Agonistas del receptor acoplado a la proteina g de la piperidina.
WO2007116229A8 (en) Heterocyclic gpcr agonists
WO2007003962A3 (en) Gpcr agonists
WO2007003961A3 (en) Gpcr agonists
ATE557024T1 (de) Piperidinverbindungen als gpcr-agonisten
GB0812642D0 (en) Compounds
WO2007116230A8 (en) Azetidine derivatives as g-protein coupled receptor (gpr119 ) agonists
MA32467B1 (fr) Derives de piperidinyle agonistes de gpcr
TN2012000152A1 (en) Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes
CY1112474T1 (el) Πιπεριδινικοι gpcr αγωνιστες
TN2012000002A1 (en) Gpr119 agonists
WO2009016462A3 (en) Substituted bicyclolactam compounds
NO20080052L (no) G-Protein kopplede reseptoragonister
TW200640867A (en) Pyridine-3-carboxamide derivatives as CB1 inverse agonists
MX2009012285A (es) Inhibidores de diacilglicerol aciltransferasa.
GEP20115241B (en) Indole compound
IL187005A0 (en) Diacylglycerol acyltransferase inhibitors
WO2008040649A3 (en) Pyrazine-2-carboxamide derivatives as cb2 receptor modulators
WO2010052144A3 (en) Neuropeptide-2-receptor (y-2r) agonists and uses thereof
MX2008013196A (es) 5-amido-2-carboxiamida-indoles.
IN2012DN03042A (enExample)
TW200806311A (en) Neuropeptide-2 receptor-agonists
MX2010003761A (es) Benzotiazoles como moduladores del receptor de grelina.
WO2010097576A8 (en) 1, 4-disubstituted piperidines as vasopressin receptor via antagonists